Drug Search Results
More Filters [+]

Azasetron

Alternative Names: azasetron
Latest Update: 2023-11-22
Latest Update Note: Clinical Trial Update

Product Description

Azasetron (Serotone) is a potent and selective 5-HT3 receptor antagonist, and classified as benzamide derivative. It has a different chemical structure from indole-type 5-HT3 receptor antagonists such as granisetron, ondansetron, ramosetron and tropisetron. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10396331/)

Mechanisms of Action: 5-HT3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sensorion
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Azasetron

Countries in Clinic: Australia, France

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Hearing Loss

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NOTOXIS

P2

Recruiting

Hearing Loss

2024-06-01

24%

NOTOXIS

P2

Recruiting

Hearing Loss

2024-06-01

24%

SENS-401-203

P2

Recruiting

Hearing Loss

2023-12-01

24%

SENS-401-203

P2

Recruiting

Hearing Loss

2023-12-01

24%

Recent News Events